Goldman Sachs Group Inc In8 Bio, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in In8 Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 10,193 shares of INAB stock, worth $2,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,193

Holding current value

$2,752

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 11, 2025	BUY	$0.23 - $0.48 $2,344 - $4,892	10,193 New	10,193 $2,000
Q1 2024 May 15, 2024	BUY	$0.95 - $1.69 $11,031 - $19,624	11,612 New	11,612 $13,000

Others Institutions Holding INAB

# of Institutions

Shares Held

30M

Call Options Held

Put Options Held

Bios Capital Management, LP Fort Worth, TX

8.6M
Shares

$2.32 Million
2.31% of portfolio
Aigh Capital Management LLC Baltimore, MD

6.19M
Shares

$1.67 Million
0.68% of portfolio
Franklin Resources Inc San Mateo, CA

5.7M
Shares

$1.54 Million
0.0% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

5.06M
Shares

$1.37 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

1.42M
Shares

$384,452
0.0% of portfolio

View Full List

About IN8BIO, INC.

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.62M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

More about INAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account